Barbara Ink

1.6k total citations
49 papers, 1.3k citations indexed

About

Barbara Ink is a scholar working on Immunology, Rheumatology and Hematology. According to data from OpenAlex, Barbara Ink has authored 49 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Immunology, 29 papers in Rheumatology and 19 papers in Hematology. Recurrent topics in Barbara Ink's work include Psoriasis: Treatment and Pathogenesis (28 papers), Spondyloarthritis Studies and Treatments (27 papers) and Autoimmune and Inflammatory Disorders Research (19 papers). Barbara Ink is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (28 papers), Spondyloarthritis Studies and Treatments (27 papers) and Autoimmune and Inflammatory Disorders Research (19 papers). Barbara Ink collaborates with scholars based in United Kingdom, United States and Germany. Barbara Ink's co-authors include David J. Pickup, Wolfgang K. Joklik, Caroline A. Ray, Ronald T. Hay, Gérard I. Evan, Jason Coarse, Iain B. McInnes, Joseph F. Merola, Christopher T. Ritchlin and Alice B. Gottlieb and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Barbara Ink

44 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Barbara Ink United Kingdom	15	489	488	354	287	248	49	1.3k
Begoña Galocha Spain	16	709 1.4×	288 0.6×	219 0.6×	356 1.2×	60 0.2×	26	1.2k
Marilyn Diaz United States	25	1.2k 2.5×	966 2.0×	101 0.3×	165 0.6×	233 0.9×	48	2.2k
Pieter Spee Denmark	20	1.4k 2.9×	557 1.1×	56 0.2×	183 0.6×	68 0.3×	32	1.9k
Rayk Behrendt Germany	17	1.3k 2.7×	1.1k 2.2×	96 0.3×	204 0.7×	119 0.5×	45	1.9k
Helen Cumming Australia	10	667 1.4×	403 0.8×	75 0.2×	194 0.7×	116 0.5×	13	1.2k
Sabine Wittmann Germany	21	971 2.0×	440 0.9×	62 0.2×	941 3.3×	311 1.3×	34	2.1k
Robert W. Maul United States	23	972 2.0×	781 1.6×	49 0.1×	229 0.8×	99 0.4×	50	1.8k
James C. Neil United Kingdom	26	512 1.0×	769 1.6×	42 0.1×	536 1.9×	550 2.2×	55	1.9k
Adrian Kelly United Kingdom	7	1.3k 2.6×	653 1.3×	67 0.2×	168 0.6×	42 0.2×	9	1.9k
H G Bedigian United States	18	435 0.9×	540 1.1×	40 0.1×	95 0.3×	72 0.3×	44	1.2k

Countries citing papers authored by Barbara Ink

Since Specialization

Citations

This map shows the geographic impact of Barbara Ink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Ink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Ink more than expected).

Fields of papers citing papers by Barbara Ink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Ink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Ink. The network helps show where Barbara Ink may publish in the future.

Co-authorship network of co-authors of Barbara Ink

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Ink. A scholar is included among the top collaborators of Barbara Ink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Ink. Barbara Ink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gladman, Dafna, Philip J. Mease, Laure Gossec, et al.. (2025). Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies. The Journal of Rheumatology. 52(5). 466–478.

Merola, Joseph F., Philip J. Mease, Atul Deodhar, et al.. (2024). P171 Bimekizumab impact on core group for research and assessment of psoriasis and psoriatic arthritis domains for patients with psoriatic arthritis: 52-week results from four phase 3 studies. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Tillett, William, Peter Nash, Laura C. Coates, et al.. (2024). Association of achieving clinical disease control criteria and patient-reported outcomes in bimekizumab-treated patients with active psoriatic arthritis: results from two phase III studies. Therapeutic Advances in Musculoskeletal Disease. 16. 1759720X241288071–1759720X241288071.

Gossec, Laure, Ana‐Maria Orbai, Laura C. Coates, et al.. (2024). Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis. RMD Open. 10(1). e003548–e003548. 1 indexed citations

Mease, Philip J., Joseph F. Merola, Yoshiya Tanaka, et al.. (2024). Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies. Rheumatology and Therapy. 11(5). 1363–1382. 4 indexed citations

Coates, Laura C., Robert Landewé, Iain B. McInnes, et al.. (2024). Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 10(1). e003855–e003855. 18 indexed citations

McInnes, Iain B., Philip J. Mease, Yoshiya Tanaka, et al.. (2023). POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL. Annals of the Rheumatic Diseases. 82. 1133–1134. 3 indexed citations

Ritchlin, Christopher T., Laura C. Coates, Iain B. McInnes, et al.. (2023). Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Annals of the Rheumatic Diseases. 82(11). 1404–1414. 30 indexed citations

Tillett, William, Joseph F. Merola, Yoshiya Tanaka, et al.. (2023). POS1534 BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUG-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WHO WERE RESPONDERS AT WEEK 16: RESULTS FROM BE OPTIMAL, A PHASE 3, ACTIVE-REFERENCE STUDY. Annals of the Rheumatic Diseases. 82. 1130–1131. 3 indexed citations

10.

McInnes, Iain B., et al.. (2023). P171 Bimekizumab in bDMARD-naïve patients with active psoriatic arthritis: improvements in PsARC over 24 weeks in the Phase 3 BE OPTIMAL trial. Lara D. Veeken. 62(Supplement_2). 1 indexed citations

11.

Merola, Joseph F., Akihiko Asahina, Paolo Gisondi, et al.. (2023). 43744 Bimekizumab in bDMARD-naïve patients with psoriatic arthritis and skin involvement: Analysis of radiographic progression at Week 16 of BE OPTIMAL, a phase 3, multicenter, randomized, placebo- controlled, active reference study. Journal of the American Academy of Dermatology. 89(3). AB128–AB128. 1 indexed citations

12.

Poddubnyy, Denis, Lianne S. Gensler, Philip J. Mease, et al.. (2023). AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES. Annals of the Rheumatic Diseases. 82. 1686–1687. 1 indexed citations

13.

Coates, Laura C., R. B. M. Landewé, Iain B. McInnes, et al.. (2023). POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR. Annals of the Rheumatic Diseases. 82. 346–347. 6 indexed citations

14.

Coates, Laura C., Iain B. McInnes, Joseph F. Merola, et al.. (2022). Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three‐Year Results From a Phase IIb Randomized Controlled Trial and Its Open‐Label Extension Study. Arthritis & Rheumatology. 74(12). 1959–1970. 27 indexed citations

15.

McInnes, Iain B., R. B. M. Landewé, Philip J. Mease, et al.. (2022). LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY. Annals of the Rheumatic Diseases. 81. 206–207. 6 indexed citations

16.

McInnes, Iain B., Akihiko Asahina, Laura C. Coates, et al.. (2022). Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL). The Lancet. 401(10370). 25–37. 95 indexed citations

17.

Merola, Joseph F., Robert Landewé, Iain B. McInnes, et al.. (2022). Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). The Lancet. 401(10370). 38–48. 104 indexed citations

18.

Meinecke, Ingmar, Anja Baier, Marvin Peters, et al.. (2007). Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proceedings of the National Academy of Sciences. 104(12). 5073–5078. 110 indexed citations

19.

Künzler, Peter, et al.. (2007). Effects of a novel tyrosine kinase inhibitor in rheumatoid arthritis synovial fibroblasts. Annals of the Rheumatic Diseases. 67(3). 389–394. 8 indexed citations

20.

Shen, Linnan, et al.. (2003). NEDP1, a Highly Conserved Cysteine Protease That deNEDDylates Cullins. Journal of Biological Chemistry. 278(28). 25637–25643. 170 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact